TY - JOUR
T1 - Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese han population
AU - Fan, Weiwei
AU - Zhou, Keke
AU - Hu, Dezhi
AU - Song, Xiao
AU - Zhao, Yingjie
AU - Chen, Hongyan
AU - Wei, Qingyi
AU - Chen, Gong
AU - Shi, Jinlong
AU - Du, Guhong
AU - Mao, Ying
AU - Lu, Daru
AU - Zhou, Liangfu
PY - 2012/10
Y1 - 2012/10
N2 - Matrix metallopeptidases (MMPs) play an important role in central nervous system tumor growth, invasion and spreading. The currently available data provide clear evidence for the involvement of MMP3 in the pathophysiology of glioma. The study aims to explore the association of single nucleotide polymorphisms (SNPs) across the MMP3 gene with glioma risk. Three haplotype tagging and additional two promoter SNPs were genotyped among 766 glioma patients and 824 cancer-free controls from East China. None of these polymorphisms alone had a significant effect on risk of gliomas. However, when three promoter polymorphisms were evaluated together by the number of putative risk of genotypes (i.e., rs645419AA, 632478CA+AA, rs522616AA), a statistically significantly increased risk of gliomas was associated with the combined genotypes with two to three risk genotypes, compared with those with zero to one risk genotypes (adjusted odds ratio (OR)=1.32; 95% confidence interval (CI)=1.03-1.68). This increased risk was also more pronounced among adults (adjusted OR=1.14, 95%CI=1.02-1.27), males (adjusted OR=1.19, 95%CI=1.05-1.36), smokers (adjusted OR=1.28, 95%CI=1.07-1.52), subjects with no family history of cancer (adjusted OR=1.21, 95%CI=1.07-1.37), and patients with nonastrocytic gliomas (adjusted OR=1.23, 95%CI=1.06-1.43). In summary, our results suggest that any one of MMP3 variants may not have a substantial effect on glioma risk, but a joint effect of MMP3 promoter polymorphisms may contribute to risk of gliomas, particularly for adult gliomas.
AB - Matrix metallopeptidases (MMPs) play an important role in central nervous system tumor growth, invasion and spreading. The currently available data provide clear evidence for the involvement of MMP3 in the pathophysiology of glioma. The study aims to explore the association of single nucleotide polymorphisms (SNPs) across the MMP3 gene with glioma risk. Three haplotype tagging and additional two promoter SNPs were genotyped among 766 glioma patients and 824 cancer-free controls from East China. None of these polymorphisms alone had a significant effect on risk of gliomas. However, when three promoter polymorphisms were evaluated together by the number of putative risk of genotypes (i.e., rs645419AA, 632478CA+AA, rs522616AA), a statistically significantly increased risk of gliomas was associated with the combined genotypes with two to three risk genotypes, compared with those with zero to one risk genotypes (adjusted odds ratio (OR)=1.32; 95% confidence interval (CI)=1.03-1.68). This increased risk was also more pronounced among adults (adjusted OR=1.14, 95%CI=1.02-1.27), males (adjusted OR=1.19, 95%CI=1.05-1.36), smokers (adjusted OR=1.28, 95%CI=1.07-1.52), subjects with no family history of cancer (adjusted OR=1.21, 95%CI=1.07-1.37), and patients with nonastrocytic gliomas (adjusted OR=1.23, 95%CI=1.06-1.43). In summary, our results suggest that any one of MMP3 variants may not have a substantial effect on glioma risk, but a joint effect of MMP3 promoter polymorphisms may contribute to risk of gliomas, particularly for adult gliomas.
KW - Cumulative effect
KW - Genetic susceptibility
KW - Glioma
KW - MMP3
KW - Polymorphism
UR - http://www.scopus.com/inward/record.url?scp=84867142596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867142596&partnerID=8YFLogxK
U2 - 10.1002/mc.20842
DO - 10.1002/mc.20842
M3 - Article
C2 - 21853476
AN - SCOPUS:84867142596
SN - 0899-1987
VL - 51
SP - E1-E10
JO - Molecular Carcinogenesis
JF - Molecular Carcinogenesis
IS - SUPPL. 1
ER -
